JP2016525092A5 - - Google Patents

Download PDF

Info

Publication number
JP2016525092A5
JP2016525092A5 JP2016524330A JP2016524330A JP2016525092A5 JP 2016525092 A5 JP2016525092 A5 JP 2016525092A5 JP 2016524330 A JP2016524330 A JP 2016524330A JP 2016524330 A JP2016524330 A JP 2016524330A JP 2016525092 A5 JP2016525092 A5 JP 2016525092A5
Authority
JP
Japan
Prior art keywords
pyrrole
methyl
carboxylate
octahydropyrrolo
hexafluoropropan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016524330A
Other languages
English (en)
Japanese (ja)
Other versions
JP6647592B2 (ja
JP2016525092A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/045145 external-priority patent/WO2015003002A1/en
Publication of JP2016525092A publication Critical patent/JP2016525092A/ja
Publication of JP2016525092A5 publication Critical patent/JP2016525092A5/ja
Application granted granted Critical
Publication of JP6647592B2 publication Critical patent/JP6647592B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016524330A 2013-07-03 2014-07-01 ピロロピロールカルバメート、および関連する有機化合物、医薬組成物、ならびにその医学的使用 Expired - Fee Related JP6647592B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361842543P 2013-07-03 2013-07-03
US61/842,543 2013-07-03
PCT/US2014/045145 WO2015003002A1 (en) 2013-07-03 2014-07-01 Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof

Publications (3)

Publication Number Publication Date
JP2016525092A JP2016525092A (ja) 2016-08-22
JP2016525092A5 true JP2016525092A5 (enExample) 2017-08-10
JP6647592B2 JP6647592B2 (ja) 2020-02-14

Family

ID=52144176

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016524330A Expired - Fee Related JP6647592B2 (ja) 2013-07-03 2014-07-01 ピロロピロールカルバメート、および関連する有機化合物、医薬組成物、ならびにその医学的使用

Country Status (7)

Country Link
US (1) US9828379B2 (enExample)
EP (1) EP3016653A4 (enExample)
JP (1) JP6647592B2 (enExample)
CN (1) CN105517547A (enExample)
CA (1) CA2917050A1 (enExample)
MX (1) MX2015017961A (enExample)
WO (1) WO2015003002A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2793148T3 (es) 2012-01-06 2020-11-13 Lundbeck La Jolla Research Center Inc Compuestos de carbamato y métodos para fabricarlos y usarlos
JP6647592B2 (ja) 2013-07-03 2020-02-14 ルンドベック ラ ホーヤ リサーチ センター,インク. ピロロピロールカルバメート、および関連する有機化合物、医薬組成物、ならびにその医学的使用
UA121775C2 (uk) 2015-07-31 2020-07-27 Пфайзер Інк. 1,1,1-трифтор-3-гідроксипропан-2-ілкарбаматні похідні та 1,1,1-трифтор-4-гідроксибутан-2-ілкарбаматні похідні як інгібітори magl
US10463753B2 (en) 2016-02-19 2019-11-05 Lundbeck La Jolla Research Center, Inc. Radiolabeled monoacylglycerol lipase occupancy probe
ES2861648T3 (es) * 2016-05-12 2021-10-06 Lundbeck La Jolla Research Center Inc Compuestos de espirociclo y procedimientos de fabricación y uso de los mismos
US10899737B2 (en) 2016-09-19 2021-01-26 Lundbeck La Jolla Research Center, Inc. Piperazine carbamates and methods of making and using same
EP3541807B1 (en) 2016-11-16 2021-09-29 H. Lundbeck A/S A crystalline form of a magl inhibitor
JOP20190106A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190105A1 (ar) * 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
AU2017361254B2 (en) * 2016-11-16 2021-09-23 H. Lundbeck A/S. Pharmaceutical formulations
KR20190104405A (ko) * 2017-01-20 2019-09-09 화이자 인코포레이티드 Magl 억제제로서의 1,1,1-트리플루오로-3-히드록시프로판-2-일 카르바메이트 유도체
HRP20241558T1 (hr) 2017-03-13 2025-03-28 Lundbeck La Jolla Research Center, Inc. Dvojni inhibitori magl i faah
CR20200088A (es) * 2017-08-29 2020-04-08 Lundbeck La Jolla Research Center Inc Compuestos espirocíclicos y sus métodos de preparación y uso
CA3072923A1 (en) 2017-08-29 2019-03-07 Lundbeck La Jolla Research Center, Inc. Spirocycle compounds and methods of making and using same
EP3689879B1 (en) * 2017-09-29 2025-02-12 Takeda Pharmaceutical Company Limited Heterocyclic compound
CR20200545A (es) 2018-05-15 2020-12-17 Lundbeck La Jolla Research Center Inc Inhibidores magl
US20210309669A1 (en) * 2018-07-19 2021-10-07 Pfizer Inc. Heterocyclic Spiro Compounds As MAGL Inhibitors
WO2021062232A1 (en) * 2019-09-26 2021-04-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for reducing rewarding effects of morphine without affecting its analgesic effects
CN115427403A (zh) 2020-04-21 2022-12-02 H.隆德贝克有限公司 单酰基甘油脂肪酶抑制剂的合成
TWI904281B (zh) 2020-11-13 2025-11-11 丹麥商H 朗德貝克公司 Magl抑制劑
TW202304932A (zh) 2021-04-01 2023-02-01 日商小野藥品工業股份有限公司 Abhd6拮抗劑
CA3242372A1 (en) 2021-12-29 2023-07-06 Psy Therapeutics, Inc. Inhibiting monoacylglycerol lipase (magl)
AU2023264787A1 (en) 2022-05-04 2024-10-31 H. Lundbeck A/S Crystalline form of 1,1,1,3,3,3-hexafluoropropan-2-yl (s)-1-(pyridazin-3-ylcarbamoyl)-6 azaspiro[2.5]octane-6-carboxylate as monoacylglycerol lipase inhibitor.
JP2024052624A (ja) * 2022-09-30 2024-04-11 小野薬品工業株式会社 Abhd6アンタゴニストを含有する医薬組成物
EP4665718A1 (en) * 2023-02-13 2025-12-24 Apogee Pharmaceuticals, Inc. Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100326D0 (sv) * 2001-02-02 2001-02-02 Astrazeneca Ab New compounds
CA2440803A1 (en) * 2001-03-07 2002-09-12 Pfizer Products Inc. Modulators of chemokine receptor activity
US20110071180A1 (en) 2008-03-05 2011-03-24 Targacept, Inc. Sub-type selective amides of diazabicycloalkanes
MX2012004753A (es) * 2009-10-23 2012-09-07 Janssen Pharmaceutica Nv Octahidropirrolo[3,4-c]pirrolos disustituidos como moduladores del receptor de orexina.
AU2011223898A1 (en) * 2010-03-04 2012-09-13 Merck Sharp & Dohme Corp. Positive allosteric modulators of mGluR2
EP2444084A1 (en) * 2010-10-21 2012-04-25 Centro Nacional de Investigaciones Oncológicas (CNIO) Use of PI3K inibitors for the treatment of obesity
BR112015004111A2 (pt) 2012-09-25 2017-07-04 Hoffmann La Roche novos derivados bicíclicos
JP6647592B2 (ja) 2013-07-03 2020-02-14 ルンドベック ラ ホーヤ リサーチ センター,インク. ピロロピロールカルバメート、および関連する有機化合物、医薬組成物、ならびにその医学的使用

Similar Documents

Publication Publication Date Title
JP2016525092A5 (enExample)
JP2018500376A5 (enExample)
US20230234958A1 (en) Shp2 phosphatase inhibitors and methods of use thereof
JP6435323B2 (ja) 炎症性障害の治療のための新規化合物及びその医薬組成物
SI3083625T1 (en) Pyrimidopyrimidinones, useful as Wee-1 kinase inhibitors
JP2013523884A5 (enExample)
DK2552920T3 (en) UNKNOWN UNKNOWN NK-3 RECEPTOR SELECTIVE ANTAGONIST RELATIONS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTOR-MEDIUM DISORDERS
RU2019115115A (ru) Производные пиперидина в качестве ингибиторов убиквитин-специфической протеазы 7
JP2011511034A5 (enExample)
JP2015510938A5 (enExample)
JP2021506858A5 (enExample)
HRP20210177T1 (hr) Supstituirani spojevi pirazolo[1,5-a]piridina kao inhibitori ret kinaze
JP2011516558A5 (enExample)
FI3436461T3 (fi) Pyrrolotriatsiiniyhdisteitä tam-inhibiittoreina
JP2014506929A5 (enExample)
JPWO2020005873A5 (enExample)
JP2017530960A5 (enExample)
JP2015522002A5 (enExample)
RU2017105296A (ru) Новые соединения
US20230406860A1 (en) Heterocyclic spiro compounds and methods of use
HRP20210935T1 (hr) Spojevi 5-kloro-2-difluorometoksifenil pirazolopirimidina koji predstavljaju inhibitore jak
RU2005117383A (ru) Производные фенилаланина в качестве ингибиторов дипептидилпептидазы для лечения или профилактики диабета
JP2018527353A5 (enExample)
JPWO2020005877A5 (enExample)
JP2014511355A5 (enExample)